Pulmonx Corporation reported financial results for the second quarter ended June 30, 2026. Worldwide revenue decreased 5% to $22.8 million, driven by a lack of sales in China while international revenue excluding China grew 12%. The company achieved a record gross margin of 78%, and operating expenses fell 16% to $26.8 million due to cost realignment efforts. Net loss narrowed to $10.1 million ($0.24 per share) from $15.2 million in the prior year period, with adjusted EBITDA loss reducing by 39%. Cash and cash equivalents stood at $55.8 million as of June 30, 2026. The company maintained its full-year 2026 revenue guidance between $90 million and $92 million. Pulmonx Corporation operates in the medical device industry, developing minimally invasive treatments for chronic obstructive pulmonary disease (COPD).